116 results on '"Buell, Jennifer"'
Search Results
2. Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT)
3. Author Correction: Molecular mechanism of phosphopeptide neoantigen immunogenicity
4. Molecular mechanism of phosphopeptide neoantigen immunogenicity
5. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
6. Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
7. Screening and Brief Intervention With Low-Income Youth in Community-Based Settings
8. Biocidal Efficacies of Contact Lens Disinfecting Solutions Against Gram-Negative Organisms Associated with Lens Case-Associated Corneal Infiltrative Events.
9. Biocidal Efficacies of Contact Lens Disinfecting Solutions Against International Organization for Standardization (ISO) Compendial Organisms
10. Investing in Distressed Communities : Outcomes From the Neighborhood Stabilization Program
11. Molecular mechanism of phosphopeptide neoantigen immunogenicity
12. Virtual Community Engagement Studio (V-CES): Engaging Mothers With Mental Health and Substance Use Conditions in Research
13. Vitamin D and neurocognitive dysfunction: Preventing “D”ecline?
14. Vitamin D is associated with cognitive function in elders receiving home health services
15. Abstract 1878: Fc-enhanced anti-CTLA-4 antibody, AGEN1181: new mechanistic insights for potent antitumor immunity and combination potential in treatment-resistant solid tumors
16. Abstract 1677: Characterization of the pharmacodynamic activity of AGEN1181, an Fc-enhanced CTLA-4 antibody, alone and in combination with the PD-1 antibody balstilimab
17. Poor iron status is more prevalent in Hispanic than in non-Hispanic white older adults in Massachusetts
18. 253 Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity
19. 267 Pseudoprogression patterns: Analysis from 2 independent phase-2 studies with immunotherapy for recurrent cervical cancer
20. 377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects
21. 70 Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro
22. Abstract 922: Expanding the therapeutic potential of anti-PD-1 and anti-CTLA-4 therapy with innovative Fc engineering and rationale combinations for the treatment of solid tumors
23. Abstract 1377: Identification and validation of WRN as a novel synthetic lethality target in context of microsatellite instability
24. AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody with improved therapeutic potential for the treatment of patients with advanced malignancies.
25. Executive Dysfunction in Homebound Older People with Diabetes Mellitus
26. Mutation-Derived Neoantigens for Cancer Immunotherapy
27. Abstract 2390: FcgR co-engagement by anti-TIGIT monoclonal antibodies enhances T cell functionality and antitumor immune responses
28. Preclinical functional characterization of AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody for the treatment of patients with early and advanced malignancies.
29. Abstract 2721: Selective FcγR engagement by CTLA-4 antibodies results in increased functional activity
30. Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens
31. Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.
32. Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.
33. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody
34. Abstract 4703: INCAGN1949, an anti-OX40 antibody with an optimal agonistic profile and the ability to selectively deplete intratumoral regulatory T cells
35. Abstract 3654: AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model
36. Abstract 4609: Agenus’ next generation cancer vaccine platforms
37. Abstract 3643: INCAGN1876, a unique GITR agonist antibody that facilitates GITR oligomerization
38. Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.
39. Abstract A037: The Agenus Immunogenic Mutation platform (AIM™) generates synthesis-ready blueprints for the AutoSynVax™ vaccine patient-specific neo-antigen vaccine
40. Abstract 5005: AGEN1884 and AGEN2041: Two functionally distinct anti-CTLA-4 antagonist antibodies
41. Abstract A109: Exploring neo-antigens and immunological response in GBM patients after individualized Prophage vaccination
42. Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model
43. Which Way to Recovery? Housing Market Outcomes and the Neighborhood Stabilization Program
44. The Evaluation of the Neighborhood Stabilization Program
45. Which Way to Recovery? Housing Market Outcomes and the Neighborhood Stabilization Program
46. 25‐Hydroxyvitamin D is associated with cognitive function in an elderly population receiving homecare services
47. The Nutrition, Aging, and Memory in Elders (NAME) study: design and methods for a study of micronutrients and cognitive function in a homebound elderly population
48. Executive Dysfunction in Homebound Older People with Diabetes Mellitus
49. Executive Dysfunction in Homebound Older People with Diabetes Mellitus.
50. 25-hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.